Graduated with BS from Nanjing University, one of the best universities in China, Yuan Lin obtained his PhD degree in Biology in Ohio State University. Dr. Yuan Lin then completed 4-year postdoc training in UCLA medical center, working with Dr. Steven Dubinett and Dr. Maie St. John on cancer immunotherapy. Dr. Yuan Lin is currently a Scientific Associate in La Jolla Institute for Immunology.
Dr. Yuan Lin has more than ten years research experience in first-class US research institutes and is an expert on cancer biology and immunotherapy area. He is interested in different approaches to regulate T cell in cancer environment. His research projects include: Adenosine receptor and IDO inhibitor anti-cancer study, genetically modified immune cell with chemokine as novel cancer immunotherapy, PI3K signaling in T cell activation, as well as function of NKT cell in cancer immunology. Dr. Yuan Lin also worked on molecular mechanism to illustrate cancer metastasis and other immune related diseases.
Lin Y*, Sharma S, St John, M. CCL21 Cancer Immunotherapy. Cancers. 2014, 6, 1098-1110; doi:10.3390 (* corresponding author)
Lin Y, Luo J, Sharma S, Dubinett S, St John, M. A Cytokine/Chemokine Delivering Dendritic Cell Polymer Is Effective in Reducing Tumor Burden in an HNSCC Murine Model. Otolaryngology-Head and Neck Surgery. 2014 May 13. pii: 0194599814533775.
Lin Y, Luo J, Sharma S, Dubinett S, St John, M. p53 modulates NF-κB mediated epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma. Oral Oncology. 2015 Oct;51(10):921-8. doi: 10.1016
Lin Y, Jon MC, Wang G, Luo J, Sharma S, Dubinett S, St John, M. p38 MAPK Mediates Epithelial-Mesenchymal Transition by Regulating p38IP and Snail in Head and Neck Squamous Cell Carcinoma. Oral Oncology. 2016 60: 81-89. doi: http://dx.doi.org/10.1016/j.oraloncology.2016.06.010